[go: up one dir, main page]

PL2167117T3 - Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi - Google Patents

Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi

Info

Publication number
PL2167117T3
PL2167117T3 PL08759229T PL08759229T PL2167117T3 PL 2167117 T3 PL2167117 T3 PL 2167117T3 PL 08759229 T PL08759229 T PL 08759229T PL 08759229 T PL08759229 T PL 08759229T PL 2167117 T3 PL2167117 T3 PL 2167117T3
Authority
PL
Poland
Prior art keywords
vwf
therapy
prophylactic treatment
bleeding disorders
extravascular administration
Prior art date
Application number
PL08759229T
Other languages
English (en)
Inventor
Ulrich Kronthaler
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2167117T3 publication Critical patent/PL2167117T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08759229T 2007-06-13 2008-06-13 Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi PL2167117T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07011545 2007-06-13
PCT/EP2008/004770 WO2008151817A1 (en) 2007-06-13 2008-06-13 Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
EP08759229A EP2167117B1 (en) 2007-06-13 2008-06-13 Use of vwf stabilized fviii preparations for extravascular administration in the therapy and prophylactic treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
PL2167117T3 true PL2167117T3 (pl) 2013-01-31

Family

ID=38219491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08759229T PL2167117T3 (pl) 2007-06-13 2008-06-13 Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi

Country Status (10)

Country Link
US (1) US9107902B2 (pl)
EP (2) EP2486936A1 (pl)
JP (1) JP2010529155A (pl)
KR (1) KR20100019999A (pl)
AU (1) AU2008261261B2 (pl)
CA (1) CA2690218C (pl)
DK (1) DK2167117T3 (pl)
ES (1) ES2392569T3 (pl)
PL (1) PL2167117T3 (pl)
WO (1) WO2008151817A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007150A (es) 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CA2728047C (en) * 2008-06-24 2019-07-30 Octapharma Ag A process of purifying coagulation factor viii
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
JP2019043961A (ja) * 2010-04-20 2019-03-22 オクタファルマ・アーゲー 医薬タンパク質の新規な安定化剤
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AR086904A1 (es) * 2011-06-10 2014-01-29 Baxter Int Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)
CN102279273A (zh) * 2011-07-19 2011-12-14 苏州大学 一种血管性血友病因子瑞斯托霉素辅因子酶联免疫试剂盒
JP2015519313A (ja) * 2012-04-24 2015-07-09 ノヴォ ノルディスク アー／エス 血友病の治療に適する医薬組成物
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CN106414492B (zh) 2014-06-06 2021-07-06 奥克塔法马股份有限公司 包含因子viii和冯·维勒布兰德因子肽的制剂
US11155601B2 (en) * 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
US10688157B2 (en) * 2015-05-22 2020-06-23 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for treating hemophilia
CN109152817A (zh) * 2016-05-20 2019-01-04 瑞士奥克特珐玛公司 具有改进的药代动力学的糖基化vwf融合蛋白
ES2908008T3 (es) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
EP3641800B1 (en) * 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
CA3069256A1 (en) * 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
WO2020160460A1 (en) 2019-02-01 2020-08-06 Baxalta Incorporated Methods of prophylactic treatment using recombinant vwf (rvwf)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586250A (en) * 1983-10-03 1986-05-06 Westinghouse Electric Corp. Apparatus for sleeving tubes in hostile environments
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
US5179385A (en) 1992-01-02 1993-01-12 International Marine Industries, Inc. Visual navigation aid with point of interest feature
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
UY30550A1 (es) 2006-08-22 2008-03-31 Boehringer Ingelheim Int Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos
AU2007340382B2 (en) * 2006-12-27 2013-06-27 Nektar Therapeutics Von Willebrand Factor- and Factor VIII-polymer conjugates having a releasable linkage

Also Published As

Publication number Publication date
US20100286047A1 (en) 2010-11-11
KR20100019999A (ko) 2010-02-19
AU2008261261B2 (en) 2013-06-27
ES2392569T3 (es) 2012-12-11
EP2167117A1 (en) 2010-03-31
US9107902B2 (en) 2015-08-18
WO2008151817A1 (en) 2008-12-18
CA2690218A1 (en) 2008-12-18
DK2167117T3 (da) 2012-11-19
EP2486936A1 (en) 2012-08-15
JP2010529155A (ja) 2010-08-26
CA2690218C (en) 2017-02-28
EP2167117B1 (en) 2012-08-15
AU2008261261A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
PL2167117T3 (pl) Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
IL178822A (en) Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders
PT2601961T (pt) Composições compreendendo lag-3 e anticorpos terapêuticos e as suas utilizações no tratamento de cancro
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
IL219876A (en) Antibodies against human 1h-7b or its fragment, preparations containing them and their use in the preparation of drugs
EP2358378A4 (en) TOPICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY DISEASE, SKIN AND SLAUGHTER DISEASES AND SIMILAR DISEASES
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
EP1971308A4 (en) TOPICALLY ADMINISTERING VOCTRIC COMPOSITION AND THERAPEUTIC FORMULATIONS COMPRISING THE SAME
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
MY173215A (en) Acetylcysteine compositions and methods of use thereof
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
HK1142823A1 (en) Formulations for the oral administration of therapeutic agents and related methods
IL212567A (en) Zaxanthin, alone or in combination with rutin, spermidine, or both, for the treatment of scalp disorders, use of zaxanthin, alone or in combination with rutin, spermidine or both, for the preparation of a medicinal or cosmetic or nutritional preparation for the treatment of scalp, and a medicinal, cosmetic or nutritional preparation containing Alone or in a mixture with routine, spermidine, or both
IL195155A (en) Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
SI2340872T1 (sl) Nove farmacevtske formulacije, uporabne v zdravljenju nespečnosti
HK1139671A1 (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders